Nimrat Grewal1, Adriana C Gittenberger-de Groot2, Marco C DeRuiter3, Robert J M Klautz4, Robert E Poelmann3, Sjoerd Duim5, Johannes H N Lindeman6, Wilke M C Koenraadt2, Monique R M Jongbloed7, Salah A Mohamed8, Hans-Hinrich Sievers8, Ad J J C Bogers9, Marie-José Goumans10. 1. Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, Netherlands Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, Netherlands. 2. Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands. 3. Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, Netherlands. 4. Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, Netherlands. 5. Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands. 6. Department of Vascular Surgery, Leiden University Medical Center, Leiden, Netherlands. 7. Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, Netherlands Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands. 8. Department of Cardiac and Thoracic Vascular Surgery, University of Lübeck, Lübeck, Germany. 9. Department of Cardiothoracic Surgery and Heart Valve Bank, Erasmus University Medical Center, Rotterdam, Netherlands. 10. Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands m.j.t.h.goumans@lumc.nl.
Abstract
OBJECTIVES: The clinical course of many patients with a bicuspid aortic valve (BAV) is complicated by ascending aortic dilatation. Currently, the indication for aortic surgery is solely based on the aortic diameter and subsequently only a small proportion of BAV patients undergoing valve surgery require concomitant ascending aortic replacement based on these recommendations. Unfortunately, a substantial number of BAV patients still develop aortic dilatation in the future and would potentially benefit from a more aggressive approach towards ascending aortic replacement. We, therefore, designed this study to identify molecular biological markers in the aortic wall predictive of aortopathy in BAV. METHODS: Ascending aortic wall specimen of BAV (n = 36) and tricuspid aortic valve (TAV) (n = 23), both without and with (>44 mm) dilatation were investigated histologically and immunohistochemically for the expression of markers for vascular remodelling [transforming growth factor (TGF)-β, phosphorylated Smad2, matrix metalloproteinase 9 (MMP9)], cellular differentiation [c-Kit, phosphorylated-c-Kit, hypoxia-inducable factor-1 alpha (HIF1α)] and haemodynamic influences on the aortic wall [endothelial nitric oxide (eNOS)]. RESULTS: All BAV patients showed significantly less inflammation (P < 0.001) and an altered intima/media ratio when compared with TAV patients. The expression of markers of a signalling pathway characteristic for cellular dedifferentiation, as exemplified by the marked expression of c-Kit, phosphorylated c-Kit and HIF1α; in the dilated BAV group was however completely comparable with only a subgroup of the non-dilated BAV (BAb), whereas the remainder of the non-dilated BAV group (BAa) was significantly distinct. This difference between the dilated BAV and BAa was further confirmed in the expression of TGF-β, phosphorylated Smad2, MMP9 and eNOS. Besides the expression pattern, similarity in the dilated BAV and BAb was also noted clinically in the most common variant of commissure position and conjoined raphe of the BAV. Based on these observations, we consider the BAb group a likely candidate for future dilatation as opposed to the BAa group. CONCLUSIONS: Using a panel of molecular tissue markers, the non-dilated BAV patients can be divided into groups susceptible and non-susceptible to aortopathy.
OBJECTIVES: The clinical course of many patients with a bicuspid aortic valve (BAV) is complicated by ascending aortic dilatation. Currently, the indication for aortic surgery is solely based on the aortic diameter and subsequently only a small proportion of BAV patients undergoing valve surgery require concomitant ascending aortic replacement based on these recommendations. Unfortunately, a substantial number of BAV patients still develop aortic dilatation in the future and would potentially benefit from a more aggressive approach towards ascending aortic replacement. We, therefore, designed this study to identify molecular biological markers in the aortic wall predictive of aortopathy in BAV. METHODS: Ascending aortic wall specimen of BAV (n = 36) and tricuspid aortic valve (TAV) (n = 23), both without and with (>44 mm) dilatation were investigated histologically and immunohistochemically for the expression of markers for vascular remodelling [transforming growth factor (TGF)-β, phosphorylated Smad2, matrix metalloproteinase 9 (MMP9)], cellular differentiation [c-Kit, phosphorylated-c-Kit, hypoxia-inducable factor-1 alpha (HIF1α)] and haemodynamic influences on the aortic wall [endothelial nitric oxide (eNOS)]. RESULTS: All BAV patients showed significantly less inflammation (P < 0.001) and an altered intima/media ratio when compared with TAV patients. The expression of markers of a signalling pathway characteristic for cellular dedifferentiation, as exemplified by the marked expression of c-Kit, phosphorylated c-Kit and HIF1α; in the dilated BAV group was however completely comparable with only a subgroup of the non-dilated BAV (BAb), whereas the remainder of the non-dilated BAV group (BAa) was significantly distinct. This difference between the dilated BAV and BAa was further confirmed in the expression of TGF-β, phosphorylated Smad2, MMP9 and eNOS. Besides the expression pattern, similarity in the dilated BAV and BAb was also noted clinically in the most common variant of commissure position and conjoined raphe of the BAV. Based on these observations, we consider the BAb group a likely candidate for future dilatation as opposed to the BAa group. CONCLUSIONS: Using a panel of molecular tissue markers, the non-dilated BAV patients can be divided into groups susceptible and non-susceptible to aortopathy.
Authors: Nimrat Grewal; Romy Franken; Barbara J M Mulder; Marie-José Goumans; Johannes H N Lindeman; Monique R M Jongbloed; Marco C DeRuiter; Robert J M Klautz; Ad J J C Bogers; Robert E Poelmann; Adriana C Gittenberger-de Groot Journal: Heart Vessels Date: 2015-07-01 Impact factor: 2.037
Authors: Betül Toprak; Katalin Szöcs; Elvin Zengin-Sahm; Christoph Sinning; Amra Hot; Peter Bannas; Kurt Hecher; Bernd Hüneke; Thomas S Mir; Meike Rybczynski; Evaldas Girdauskas; Stefan Blankenberg; Yskert von Kodolitsch Journal: J Clin Med Date: 2020-04-15 Impact factor: 4.241
Authors: Oliver J Harrison; Felino Cagampang; Sunil K Ohri; Christopher Torrens; Kareem Salhiyyah; Amit Modi; Narain Moorjani; Anthony D Whetton; Paul A Townsend Journal: J Cardiothorac Surg Date: 2018-06-22 Impact factor: 1.637
Authors: Nimrat Grewal; Adriana C Gittenberger-de Groot; Jan H Lindeman; Arthur Klautz; Antoine Driessen; Robert J M Klautz; Robert E Poelmann Journal: Ann Cardiothorac Surg Date: 2022-07
Authors: Christopher Gestrich; Georg D Duerr; Jan C Heinemann; Anne Meertz; Chris Probst; Wilhelm Roell; Wolfgang Schiller; Andreas Zimmer; Laura Bindila; Beat Lutz; Armin Welz; Oliver Dewald Journal: Biomed Res Int Date: 2015-10-11 Impact factor: 3.411
Authors: N Grewal; M C DeRuiter; M R M Jongbloed; M J Goumans; R J M Klautz; R E Poelmann; A C Gittenberger-de Groot Journal: Neth Heart J Date: 2014-09 Impact factor: 2.380
Authors: Nimrat Grewal; Adriana C Gittenberger-de Groot; Jan von der Thusen; Lambertus J Wisse; Margot M Bartelings; Marco C DeRuiter; Robert J M Klautz; Robert E Poelmann Journal: J Clin Med Date: 2020-03-26 Impact factor: 4.241